98%
921
2 minutes
20
Background: Chronic kidney disease (CKD) strongly affects prognosis in patients with heart failure (HF). However, the difference in the implementation of guideline-directed medical therapy (GDMT) during HF-related hospitalization between patients with and without CKD and its association with worsening heart failure (WHF) events remain unclear.
Methods: A post-hoc analysis was conducted using data from a retrospective, multicenter, observational registry of patients hospitalized for HF with a left ventricular ejection fraction (LVEF) of <50 %. The primary endpoint was a composite of outpatient WHF, HF-related hospitalization, and all-cause mortality.
Results: Of the 442 patients, 246 had CKD (56 %). These patients were older and had a higher prevalence of HF. At admission, the GDMT score was higher in patients with CKD than in those without CKD [3 (interquartile range, 1-5) vs. 1 (0-4)]; at discharge, the GDMT score was lower in patients with CKD [5 (3-7) vs. 6 (4.5-8)]. Optimized GDMT implementation at discharge, defined as a GDMT score of ≥6, was independently associated with improved prognosis in both groups.
Conclusions: In-hospital GDMT implementation was less optimized in patients with CKD compared with those without. Nevertheless, optimized GDMT implementation at discharge was associated with a lower incidence of adverse events, regardless of CKD status, among patients hospitalized with HF.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jjcc.2025.08.007 | DOI Listing |
Cardiovasc Toxicol
September 2025
Department of Cardiac Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangdong Cardiovascular Institute, Guangzhou, 510100, Guangdong, China.
Myocardial infarction (MI), induced by ischemia and hypoxia of the coronary arteries, presents as myocardial necrosis. Patients often experience intense, prolonged retrosternal pain that is unrelieved by rest or nitrate therapy and is frequently associated with high blood myocardial enzyme levels. Physical effort may exacerbate this anxiety, increasing the likelihood of life-threatening consequences such as arrhythmias, shock, or cardiac failure.
View Article and Find Full Text PDFTrends Mol Med
September 2025
Institute of Pharmacology and Toxicology, University of Würzburg, 97078 Würzburg, Germany; Leibniz-Institut für Analytische Wissenschaften (ISAS) e.V., 44139 Dortmund, Germany. Electronic address:
Dysregulation of the RAF-MEK-ERK1/2 pathway is involved in the pathoetiology of many diseases. Its central role in cancer has led to the development of drugs targeting upstream receptors, RAS, and kinases in the extracellular signal-regulated kinase 1 (ERK1) and 2 (ERK2) signaling cascade. The use of these drugs in cancer therapy - together with ongoing monitoring of their effectiveness, evolving side-effects, and resistance mechanisms - has expanded our knowledge of both the physiological and pathological functions of ERK1/2 and could thus provide potential alternative therapeutic strategies.
View Article and Find Full Text PDFCardiovasc Revasc Med
August 2025
Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA. Electronic address:
Secondary mitral regurgitation (SMR) remains a prevalent and challenging complication in patients with heart failure (HF), associated with poor prognosis despite optimal guideline-directed medical therapy (GDMT) and cardiac resynchronization therapy. Current American and European guidelines recommend GDMT as first-line therapy, with transcatheter edge-to-edge repair (TEER) reserved for severe symptomatic SMR patients who remain refractory. However, both guidelines preceded the reporting of pivotal randomized controlled trials (RESHAPE-HF2, MATTERHORN, and EFFORT) and emerging evidence in new clinical scenarios.
View Article and Find Full Text PDFInt J Cardiol
September 2025
Federico II University, Naples, Italy; Federico II University Hospital, Naples, Italy. Electronic address:
Background: Peripartum cardiomyopathy (PPCM) is a rare, life-threatening form of heart failure occurring in late pregnancy or postpartum, with variable clinical course and outcomes. We report preliminary clinical and echocardiographic findings from a national Italian registry of PPCM patients METHODS: The study was approved by the institutional Ethics Committee and registered at ClinicalTrials.gov (NCT05878041).
View Article and Find Full Text PDFJ Vasc Interv Radiol
September 2025
Chief consultant, Heart failure clinic & Echocardiography, GKNM hospital, Coimbatore, India.